Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06774326 | Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines(AntraCardioTox) | recruiting | — | 160 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774677 | Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| 1 |
| Jan 14, 2025 |
| clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05528939 | Feasibility/Acceptability of Attentional-Control Training in Survivors(FAACTS) | recruiting | N/A | 50 | Children's National Research InstituteOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06767254 | A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence | recruiting | — | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04786028 | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | active not recruiting | Phase 2 | 72 | Canadian Myeloma Research GroupOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764524 | Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764589 | Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood | active not recruiting | — | 90 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760936 | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients(PIXBRIDGE) | active not recruiting | — | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06761274 | Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma(MEPI-AGE) | recruiting | N/A | 200 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06761599 | Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma | active not recruiting | — | 214 | Superior UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06761911 | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | not yet recruiting | Phase 4 | 100 | Xiuhua SunOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma(UHKT-CAR19-01) | recruiting | Phase 1 | 10 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758726 | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06734871 | A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06757894 | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06755619 | CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)(CAPCI) | recruiting | — | 60 | Nordic Lymphoma GroupNETWORK | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06755775 | PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma | recruiting | — | 150 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04160546 | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)(ResToP) | active not recruiting | Phase 2 | 80 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06753279 | Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs) | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Dec 31, 2024 | clinicaltrials |
| NCT05958719 | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06643195 | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia | not yet recruiting | N/A | 358 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05501379 | Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker(OncoPhys) | recruiting | — | 60 | University Medicine GreifswaldOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05690581 | Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies | recruiting | Phase 1 | 146 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05807789 | Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion(CAR_22) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | recruiting | Phase 3 | 476 | InnoCare Pharma Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06690593 | Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy | recruiting | — | 2,990 | Zhujiang HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06740916 | Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance | recruiting | Phase 3 | 240 | Siriraj HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 14, 2025source: clinicaltrials